Tanya B Dorff1, Leslie K Ballas2, Anne K Schuckman3. 1. Division of Medical Oncology, Norris Comprehensive Cancer Center, USC Keck School of Medicine, 1441 Eastlake Ave. #3440, Los Angeles, CA, 90033, USA. dorff@usc.edu. 2. Department of Radiation Oncology, Norris Comprehensive Cancer Center, USC Keck School of Medicine, 1441 Eastlake Ave., Los Angeles, CA, 90033, USA. 3. USC Institute of Urology, USC Keck School of Medicine, 1441 Eastlake Ave. 7th floor, Los Angeles, CA, 90033, USA.
Abstract
PURPOSE OF REVIEW: The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy. RECENT FINDINGS: Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease. Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease.
PURPOSE OF REVIEW: The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy. RECENT FINDINGS: Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease. Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease.
Entities:
Keywords:
Brachytherapy; EGFR; HPV; Inguinal node dissection; Organ preservation; Pelvic node dissection; Penectomy; Penile cancer
Authors: Pranav Sharma; Rosa Djajadiningrat; Kamran Zargar-Shoshtari; Mario Catanzaro; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess Journal: Urol Oncol Date: 2015-06-10 Impact factor: 3.498
Authors: Amber Flaherty; Timothy Kim; Anna Giuliano; Anthony Magliocco; Tariq S Hakky; Lance C Pagliaro; Philippe E Spiess Journal: Urol Oncol Date: 2013-11-13 Impact factor: 3.498
Authors: Jacobien M Kieffer; Rosa S Djajadiningrat; Erik A M van Muilekom; Niels M Graafland; Simon Horenblas; Neil K Aaronson Journal: J Urol Date: 2014-04-18 Impact factor: 7.450
Authors: Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-05-01 Impact factor: 11.908
Authors: Siraj M Ali; Sumanta K Pal; Kai Wang; Norma A Palma; Eric Sanford; Mark Bailey; Jie He; Julia A Elvin; Juliann Chmielecki; Rachel Squillace; Edward Dow; Deborah Morosini; Jamie Buell; Roman Yelensky; Doron Lipson; Garrett M Frampton; Peter Howley; Jeffrey S Ross; Philip J Stephens; Vincent A Miller Journal: Oncologist Date: 2015-12-15
Authors: Nicola Nicolai; Laura Maria Sangalli; Andrea Necchi; Patrizia Giannatempo; Anna Maria Paganoni; Maurizio Colecchia; Luigi Piva; Mario Achille Catanzaro; Davide Biasoni; Silvia Stagni; Tullio Torelli; Daniele Raggi; Elena Faré; Giorgio Pizzocaro; Roberto Salvioni Journal: Clin Genitourin Cancer Date: 2015-08-06 Impact factor: 2.872
Authors: Giuseppe Di Lorenzo; Carlo Buonerba; Gabriella Gaudioso; Vincenzo Gigantino; Giuseppe Quarto; Renato De Domenico; Michele Caraglia; Rossella Di Trolio; Paolo A Ascierto; Sabino De Placido; Sisto Perdonà; Renato Franco Journal: Expert Opin Ther Targets Date: 2013-03-22 Impact factor: 6.902
Authors: Andrej Panic; Henning Reis; Alina Wittka; Christopher Darr; Boris Hadaschik; Verena Jendrossek; Diana Klein Journal: Front Oncol Date: 2021-03-31 Impact factor: 6.244